EMPAA L 25+5MG TAB 28s
-
Linagliptin and Empagliflozin work together to lower blood sugar levels in individuals with type 2 diabetes. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor; it blocks the breakdown of incretin hormones, such as GLP-1 (glucagon-like peptide-1), which stimulate insulin secretion and reduce glucagon secretion in a glucose-dependent manner. This leads to increased insulin production and decreased glucagon release, resulting in better blood sugar control. Empagliflozin, on the other hand, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, promoting the elimination of glucose through urine, and lowering blood sugar levels. By combining these two mechanisms, Linagliptin and Empagliflozin provide a synergistic effect in managing blood glucose levels.
-
Ingredients
Linagliptin 5mg, Empagliflozin 25mg
-
Drug Class
DPP-4 inhibitor and SGLT2 inhibitor.
-
Dosage Form
Tablet
-
Uses
The following are the uses of Linagliptin 5mg, Empagliflozin 25mg Tablet:
- Used for managing type 2 diabetes by controlling blood sugar levels.
- Used to reduce the risk of cardiovascular events in diabetic patients.
- Used to lower blood sugar levels by inhibiting the enzyme DPP-4.
- Used to increase glucose excretion in the urine by inhibiting SGLT2.
- Used to improve glycemic control when diet and exercise alone aren't sufficient.
- Used to promote weight loss and lower blood pressure as additional benefits.
- Used to potentially reduce the risk of diabetic kidney disease progression.
- Used as part of a comprehensive diabetes management plan.